67. Therapeutic duplication would be a concern for a patient prescribed which of the following medications, if also receiving another medication with similar effects?
Answer: A
Therapeutic duplication would be a concern for a patient prescribed doxazosin.
Therapeutic duplication occurs when a patient is prescribed multiple medications that serve similar therapeutic purposes, which can lead to increased risks of side effects and complications. In this case, doxazosin, which is an alpha-blocker used primarily for hypertension and benign prostatic hyperplasia, raises concerns if combined with other medications that have similar effects.
A) doxazosin.
Doxazosin is an alpha-adrenergic antagonist that lowers blood pressure and can improve urinary flow in men with benign prostatic hyperplasia. If a patient is prescribed another medication that also acts as an alpha-blocker or has similar antihypertensive effects, this can lead to therapeutic duplication, increasing the risk of hypotension or other side effects.
B) guaifenesin.
Guaifenesin is an expectorant used primarily to relieve chest congestion. It does not have any overlapping therapeutic effects with doxazosin or any other antihypertensive medications, making it irrelevant in the context of therapeutic duplication concerning the question.
C) tamoxifen.
Tamoxifen is a selective estrogen receptor modulator used primarily in breast cancer treatment. It does not share similar effects with doxazosin; therefore, there is no concern for therapeutic duplication between these two medications.
D) baclofen.
Baclofen is a muscle relaxant used to treat spasticity. Like tamoxifen, it does not have similar effects to doxazosin and would not contribute to therapeutic duplication in the context of medications that lower blood pressure or treat similar conditions.
Conclusion
Doxazosin is the only medication listed that poses a risk of therapeutic duplication when prescribed alongside other alpha-blockers or antihypertensives, making it the focus of concern in this scenario. The other options, guaifenesin, tamoxifen, and baclofen, do not overlap in therapeutic effects with doxazosin, thus eliminating the risk of duplication. Understanding the implications of prescribing practices is crucial in preventing adverse effects in patients.